



Ontario
Rheumatology
Association

2021

ANNUAL SCIENTIFIC MEETING
MAY 28-30, 2021

Learning Objectives

The Evolution of Understanding and Treatment in Rheumatic Diseases: From Pathophysiology to Guidelines

MEETING LEARNING OBJECTIVES











By the end of the meeting, participants will be able to:






- Discuss recent developments in the diagnosis and management of rheumatic diseases;
- Appraise new rheumatologic treatment paradigms and practice resources; and
- Foster greater provincial peer mentorship and collaboration

The theme of this year's meeting is: **The Evolution of Understanding and Treatment in Rheumatic Diseases: From Pathophysiology to Guidelines**. The meeting will enable participants to engage in both clinical and scholarly activities with the objective of improving the quality of care in Ontario for patients with rheumatic diseases.

INDIVIDUAL SESSION LEARNING OBJECTIVES

	Session & Speakers	Learning Objectives
Friday Plenary Sessions	Thriving While Surviving Dr. Mamta Gautam	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Discuss the key stressors in practicing during the COVID-19 crisis 2. Define stress, burnout, and know the early danger signs of stress 3. Learn and implement the 5 C's framework to manage their stress effectively at home and at work.
Saturday Plenary Sessions	Translating Clinical Trial Observations into Pathophysiological Understanding of RA Dr. Maya Buch	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Outline the current understanding of RA pathophysiology; relating to the stages along the RA disease continuum from the at risk stage to those with poor prognostic outcomes including refractory disease and co/multi-morbidity such as cardiovascular disease. 2. Define the process of RA pathogenesis, therapeutic approaches to RA and whether emergent treatments and technologies provide the opportunity to understand disease pathogenesis further, and deliver more significant improvements in outcomes of people with RA.

	State of the Art in SLE  Dr. Michelle Petri	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Outline epidemiology and classification criteria for SLE 2. Appreciate prednisone and hydroxychloroquine risk/benefits 3. Identify new advances in non-renal lupus including JAKinibs and anifrolumab 4. Identify new advances in renal lupus including voclosporin and Obinutuzumab 5. Outline prevention of major morbidity: cardiovascular disease and thrombosis
Saturday Workshops Breakouts	1 Difficult Lupus Cases  Dr. Janet Pope	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Analyze challenging real-world Difficult SLE case presentations; 2. Identify optimal peer-developed clinical management insights and strategies
	2 Clinical Problems in AS  Dr. Robert Inman	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Analyze challenging real-world Difficult AxSpA case presentations; 2. Identify optimal peer-developed clinical management insights and strategies
	3 Difficult RA Cases  Prof. Josef Smolen	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Analyze challenging real-world Difficult RA case presentations; 2. Identify optimal peer-developed clinical management insights and strategies
	4 Primary Scleroderma Heart Involvement  Dr. Maya Buch	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Appreciate the importance of primary heart involvement in scleroderma 2. Identify the nature of its presentation and the impact on overall mortality. 3. Outline epidemiological and clinical data that identify scleroderma profiles at risk of development of heart involvement
Saturday Plenary Sessions	State of the Art in RA  Prof. Josef Smolen	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Appraise the most recent therapeutic developments in rheumatoid arthritis 2. Distinguish different clinical instruments for disease activity assessment 3. Interpret the value of a strategic approach to the management of rheumatoid arthritis
	A New Model for MSK Management in Ontario  Dr. Robert Bell	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Understand new models of referral and management for patients with MSK complaints in Ontario
	State of the Art in Axial Spondyloarthritis  Dr. Robert Inman	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Update current concepts in the pathogenesis of AxSpA 2. Review current classification of AxSpA clinical subsets 3. Appraise the most recent therapeutic developments in AxSpA
Sunday Plenary Sessions	Epidemiology of Vaccine-Preventable Infections including SARS-CoV-2 in Rheumatic Disease Patients  Dr. Jeffrey Curtis	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Identify the incidence, prevalence and severity of vaccine preventable infections in Rheumatic Disease patients 2. Outline the potential role disease modifying agents can have on susceptibility of Rheumatic Disease patients to SARS-CoV-2 infection
Sunday Poster Session	Poster Session  Dr. Lillian Barra, Dr. Leonardo Martin Calderon, Dr. Andreu Fernández-Codina, Dr. Lena Nguyen, Leslie Laing	By the end of the respective sessions, participants will be able to: <ol style="list-style-type: none"> 1. Review novel research and clinical investigations of Canadian rheumatology healthcare professionals 2. Discuss implications of current research and evidence 3. Identify opportunities for future explorations and collaborations

Sunday Workshops Breakouts	1 Communicating Risks and Benefits of Medications to Your Patients - Making Epidemiology Practical:  Dr. Jeffrey Curtis	By the end of the respective sessions, participants will be able to: 1. Outline best practices for successfully communicating complex concepts of risk/benefits to patients in a meaningful and impactful way
	2 Practice Management: Building Your Clinic & Managing Human Resources  Dr. Thanu Ruban, Dr. Yan Yeung, Dr. Viktoria Pavlova, Dr. Andy Thompson	By the end of the respective sessions, participants will be able to: 1. Discuss best practices in managing employees in your practice 2. Develop a practical guide to building out your clinic 3. Exchange ideas with colleagues on how to create a successful clinic
Sunday Workshops Breakouts	3 Checkpoint Inhibitors  Dr. Shahin Jamal	By the end of the respective sessions, participants will be able to: 1. Review the evolution of immunotherapy in cancer and its implications for rheumatologists 2. Identify the common rheumatic immune related adverse events associated with cancer immunotherapy 3. Outline optimal management of patients with rheumatic immune related adverse events including recognition, investigations and treatment
	4 New Layers of Intelligence for Personalized Medicine in Rheumatology  Dr. Jason Lee	By the end of the respective sessions, participants will be able to: 1. Identify the purpose and current limitations of personalized medicine as it relates to patient care in Rheumatology. 2. Recognize the current and emerging technologies that are driving personalized medicine, with a particular focus on artificial intelligence (AI) 3. Identify opportunities to participate in the development and utilization of personalized medicine in clinical rheumatology care.
Sunday Plenary Sessions	Psoriatic Arthritis: Overcoming Barriers to Improve Patient Outcomes  Dr. Christopher Ritchlin	By the end of the respective sessions, participants will be able to: 1. Present potential solutions to improve outcomes in PsA 2. Discuss novel potential treatment targets T resident memory cells and Arthritis Tissue Osteoclastic Macrophages 3. Review data on the effect of dietary interventions 4. Outline efforts to identify patients at risk for PsA for early therapy to delay or prevent onset of disease 5. Present recent data on head-to head trials of biologic agents in PsA

The Mission of the Ontario Rheumatology Association is to represent Ontario Rheumatologists and promote their pursuit of excellence in Arthritis care in Ontario through Leadership, Advocacy, Education and Communications.